Adult Xp11.2 translocation renal cell carcinoma managed effectively with pazopanib.

Document Type

Article

Publication Date

6-25-2021

Publication Title

BMJ Case Reports

Abstract

Xp11.2 translocation renal cell carcinoma (TRCC) is a rare and aggressive variant of renal cell carcinoma (RCC) when presenting in adults. We report a case of a man in his early 40s who was diagnosed with stage III Xp11.2 TRCC and underwent radical nephrectomy. Seven months following the surgery, an adrenal nodule and bilateral pulmonary nodules were discovered. He underwent cryoablation of the adrenal nodule and systemic treatment with daily pazopanib. He displayed stable disease for approximately 6 years. Following this period, multiple hospitalisations interrupted daily pazopanib therapy resulting in progression of disease. His regimen was then changed to ipilimumab and nivolumab, followed by current daily therapy with axitinib. The patient now shows stable disease in his 10th year after diagnosis. This case study demonstrates the efficacy of pazopanib for metastatic Xp11.2 TRCC and warrants further investigation to supplement the guidelines regarding the use of targeted therapy for TRCC.

Volume

14

Issue

6

First Page

e243058

Last Page

e243058

DOI

10.1136/bcr-2021-243058

ISSN

1757-790X

PubMed ID

34172479

Link to Full Text

Share

COinS